


NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps ID6379

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
AstraZeneca (tezepelumab)	All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
Allergy UK	Board of Community Health Councils in
Anaphylaxis UK	Wales
Asthma + Lung UK	British National Formulary
Asthma Relief Charity	Care Quality Commission
NARA – The Breathing Charity	Department of Health - Northern Ireland
Sinus UK	Healthcare Improvement Scotland
SmellTaste	Medicines and Healthcare products
South Asian Health Foundation	Regulatory Agency
Specialised Healthcare Alliance	National Association of Primary Care
The Samter's Society	National Pharmacy Association
·	NHS Confederation
Healthcare professional groups	NHS Wales Joint Commissioning
 Association of Respiratory Nurse 	Committee
Specialists	Scottish Medicines Consortium
Association for Respiratory	Welsh Government
Technology and Physiology	
Association of Surgeons of Great	Possible comparator companies
Britain and Ireland	Sanofi (dupilumab)
British Association of	
Otolaryngologists, Head & Neck	Relevant research groups
Surgeons	Asthma, Allergy and Inflammation
British Geriatrics Society	Research Trust
British Society for Allergy and Clinical	British Association for Lung Research
Immunology	Cochrane Airways Group Desired Hide Andrews and Allegrane
ENT UK National Lloopt and Lung Institute	David Hide Asthma and Allergy Page 27th Control Page 27th Contr
National Heart and Lung Institute Drimany Core Requires and Society LIK	Research Centre
Primary Care Respiratory Society UK Payer Callage of Appenting	Genomics England MBC Clinical Trials Unit
Royal College of Anaesthetists Royal College of Constal Prostitioners	MRC Clinical Trials Unit National Institute for Health Because
Royal College of General Practitioners Royal College of Nursing	National Institute for Health Research
Royal College of Nursing Payal College of Pathalogists	Associated Public Health groups
Royal College of Physicians Payel College of Physicians	
 Royal College of Physicians 	Public Health Wales



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association 	UK Health Security Agency
<u>Others</u>	
Department of Health and Social CareNHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.


The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example,





the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.